论文部分内容阅读
目的观察人尿激肽原酶(尤瑞克林)治疗进展性脑梗死的疗效。方法对86例进展性脑梗死患者随机分为治疗组43例及对照组43例,治疗组除予常规保护脑细胞、活血化瘀、抗血小板聚集治疗外,加用尤瑞克林静脉滴注。结果治疗7d后,对照组与治疗组的NIHSS评分为(13.37±4.35)vs(8.72±3.46),治疗组临床疗效明显优于对照组,且差异有统计学意义(P<0.05)。结论尤瑞克林治疗进展性脑梗死疗效显著。
Objective To observe the therapeutic effect of human kallikrein (urelin) on patients with progressive cerebral infarction. Methods A total of 86 patients with progressive cerebral infarction were randomly divided into treatment group (43 cases) and control group (43 cases). In addition to routine protection of brain cells, blood circulation and anti-platelet aggregation therapy, . Results After 7 days of treatment, the NIHSS scores of the control group and the treatment group were (13.37 ± 4.35) vs (8.72 ± 3.46), respectively. The clinical efficacy of the treatment group was significantly better than that of the control group, and the difference was statistically significant (P <0.05). Conclusion Youre Kelin treatment of progressive cerebral infarction significant effect.